Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE: Tiragolumab and atezolizumab with chemotherapy in triple negative breast cancer
2022-501561-51-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- Jun 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tiragolumab, atezolizumab, nab-paclitaxel, carboplatin, cyclophosphamide and 1 more in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by Institut Curie. Primary endpoints: Cohort A pathological complete response (pCR) rate and Cohort B 6-month progression-free survival rate (6-month PFS). Planned start Jun 2023; status: authorised.
02
Drugs
tiragolumabatezolizumabnab-paclitaxelcarboplatincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-501561-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501561-51-00.